|
1-[4-Bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea |
|---|---|
| Trade Name | |
| Orphan Indication | Glioblastoma |
| USA Market Approval | USA |
| USA Designation Date | 2017-08-07 00:00:00 |
| Sponsor | Deciphera Pharmaceuticals, LLC;500 Totten Pond Road;Waltham, Massachusetts, 02451 |
